Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What CAGR Will the Minimal Residual Disease Market Achieve During 2025–2034, and What Does It Indicate?
The market size for minimal residual disease has seen a rapid surge in recent periods. It is predicted to expand from $1.78 billion in 2024 to $2.01 billion in 2025, resulting in a compound annual growth rate (CAGR) of 12.9%. The growth witnessed in the past era is due to the rise in cancer patient numbers, escalating investment in research and development, better healthcare affordability, increased instances of blood cancer, and heightened public awareness.
The market size of minimal residual disease is predicted to undergo substantial growth in the coming years. The market value is forecasted to reach $3.22 billion in 2029, with a compound annual growth rate (CAGR) of 12.5%. This predicted growth during the forecast period is likely due to an increase in cancer patients, enhancements in governmental awareness programs, increased affordability of healthcare, rising disposable income in up-and-coming economies, and initiatives by governmental bodies to promote cancer awareness. Major upcoming trends during this period include advancements in next-generation sequencing (NGS) technology, standardized MRD testing, the adoption of personalized MRD monitoring, progress in liquid biopsy technologies, and therapies directed at minimal residual disease.
How Are the key drivers expanding the growth of the Minimal Residual Disease Market?
The escalating incidence of cancer is anticipated to drive the expansion of the minimal residual disease market in the future. Cancer encompasses a family of illnesses distinguished by the uncontrolled multiplication and dispersion of irregular cells within the body. The growing occurrence of cancer results from aspects such as an aging community, amplified contact with environmental carcinogens, unhealthy lifestyle habits, and genetic vulnerabilities. The surge in cancer incidence enhances the need for accurate MRD testing to identify remaining cancer cells, promoting early action and customized treatment. This boosts the prediction of relapses and upgrades patient results. For example, in May 2024, the National Cancer Institute (NCI), a US-based government organization, stated that nearly 20 million fresh cancer instances and 9.7 million cancer-related fatalities were registered globally in 2022. Moreover, the projections for 2040 predict approximately 29.9 million new cases and 15.3 million cancer-linked deaths. Consequently, the escalating incidence of cancer is propelling the expansion of the minimal residual disease market.
Explore Comprehensive Insights Into The Global Minimal Residual Disease Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp
Who Are the Key Firms Paving the Way for Growth in the Minimal Residual Disease Market?
Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.
What Are the Most Influential Trends Currently Shaping the Minimal Residual Disease Market?
Leading companies in the minimal residual disease (MRD) market are concentrating their efforts on creating superior in vitro diagnostic (IVD) test services. These are aimed at delivering bespoke therapy alternatives for improved patient results. An in vitro diagnostic (IVD) test service is a laboratory-based procedure used to identify remaining cancer cells following treatment. This aids in predicting recurrences and fine-tuning therapy. For instance, in December 2022, Adaptive Biotechnologies Corporation, an American biotech firm, introduced clonoSEQ Assay for the detection of minimal residual disease (MRD) in patients dealing with diffuse large B-cell lymphoma (DLBCL). This test utilizes circulating tumor DNA (ctDNA) found in blood samples to offer a highly accurate, non-intrusive method of monitoring cancer advancement and early relapse detection. The assay provides doctors with a more accurate assessment of a patient’s disease load, aiding them in customizing treatment plans. Additionally, it is the first-ever minimal residual disease (MRD) test for diffuse large B-cell lymphoma (DLBCL) to be covered by Medicare, ensuring its broad accessibility across all treatment protocols and time frames.
Secure Your Global Minimal Residual Disease Market Report Now for Fast and Efficient Delivery!
https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report
What Are the Major Segments of the Minimal Residual Disease Market and Their Role in Driving Growth?
The minimal residual disease market covered in this report is segmented –
1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets
2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques
3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions
Subsegments:
1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas
Which Regions Are Essential for the Growth of the Minimal Residual Disease Market?
North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Scope and Reach of the Minimal Residual Disease Market Defined?
Minimal residual disease (MRD) refers to the few cancer cells that persist in the body after treatment, despite clinical remission. Monitoring minimal residual disease (MRD) helps detect early signs of relapse, evaluate treatment effectiveness, and predict the risk of recurrence. This sensitive detection can guide tailored therapies to improve outcomes and reduce the likelihood of relapse.
Browse Through More Similar Reports By The Business Research Company:
Melanoma Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/melanoma-drugs-global-market-report
Melanoma Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/melanoma-therapeutics-global-market-report
Non-Alcoholic Steatohepatitis NASH Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: